Use of neoadjuvant chemotherapy prior to radical hysterectomy in cervical cancer: monitoring tumour shrinkage and molecular profile on magnetic resonance and assessment of 3-year outcome by deSouza, N M et al.
Use of neoadjuvant chemotherapy prior to radical hysterectomy
in cervical cancer: monitoring tumour shrinkage and molecular
profile on magnetic resonance and assessment of 3-year outcome
NM deSouza*,1, WP Soutter
2, G Rustin
6, MM Mahon
5, B Jones
4, R Dina
3 and GA McIndoe
2
1Department of Imaging, Hammersmith Hospital, DuCane Road, London W12 0HS, UK;
2Departments of Obstetrics and Gynaecology, Hammersmith
Hospital, DuCane Road, London W12 0HS, UK;
3Department of Histopathology, Hammersmith Hospital, DuCane Road, London W12 0HS, UK;
4Department of Radiation Oncology, Hammersmith Hospital, DuCane Road, London W12 0HS, UK;
5The Robert Steiner MR Unit, Hammersmith
Hospital, DuCane Road, London W12 0HS, UK;
6Department of Medical Oncology, Mount Vernon Hospital, Middlesex, UK
The objective of this study is to assess tumour response to neoadjuvant chemotherapy prior to radical hysterectomy in cervical
cancer using magnetic resonance (MR) to monitor tumour volume and changes in molecular profile and to compare the survival to
that of a control group. Eligibility included Stage Ib–IIb previously untreated cervical tumours 410cm
3. Neoadjuvant chemotherapy
in 22 patients (methotrexate 300mgm
 2 (with folinic acid rescue), bleomycin 30mgm
 2, cisplatin 60mgm
 2) was repeated twice
weekly for three courses and followed by radical hysterectomy. Post-operative radiotherapy was given in 14 cases. A total of 23
patients treated either with radical surgery or chemoradiotherapy over the same time period comprised the nonrandomised control
group. MR scans before and after neoadjuvant chemotherapy and in the control group documented tumour volume on imaging and
metabolites on in vivo spectroscopy. Changes were compared using a paired t-test. Survival was calculated using the Kaplan–Meier
method. There were no significant differences between the neoadjuvant chemotherapy and control groups in age (mean, s.d.
43.3710, 44.778.5 years, respectively, P¼0.63) or tumour volume (medians, quartiles 35.8, 17.8, 57.7cm
3 vs 23.0, 15.0, 37.0cm
3,
respectively, P¼0.068). The reduction in tumour volume post-chemotherapy (median, quartiles 7.5, 3.0, 19.0cm
3) was significant
(P¼0.002). The reduction in –CH2 triglyceride approached significance (P¼0.05), but other metabolites were unchanged. The 3-year
survival in the chemotherapy group (49.1%) was not significantly different from the control group (46%, P¼0.94). There is a significant
reduction in tumour volume and –CH2 triglyceride levels after neoadjuvant chemotherapy, but there is no survival advantage.
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Neoadjuvant chemotherapy has been advocated prior to radical
hysterectomy in locally advanced cervical carcinoma because it
may serve to control micrometastatic disease and so improve
survival (Sardi et al, 1997; Benedetti-Panici et al, 1998; Hwang et al,
2001). In addition, it offers the potential to reduce tumour volume
and thus improve surgical resectability (Eddy et al, 1995).
However, the implementation of a chemotherapeutic regime delays
surgery by 6 weeks, with the potential for transforming a surgically
resectable tumour to one that is not. The purpose of this study was
to assess tumour response to neoadjuvant chemotherapy prior to
radical hysterectomy in cervical cancer using magnetic resonance
imaging to monitor tumour volume and magnetic resonance
spectroscopy to assess change in molecular profile. The survival
was compared to that of a control group of equivalent stage and
tumour volume who were treated conventionally either with
radical surgery or chemoradiotherapy over the same time period.
PATIENTS AND METHODS
All women presenting to our gynaecological oncology surgical
centre and assessed as being potential candidates for radical
hysterectomy underwent magnetic resonance imaging using a
conventional plus an endovaginal technique. Over the 57-month
period March 1996–December 2000, all patients with tumour
volume 410cm
3 and Stage Ib–IIb were included in this study:
those from one oncological referral centre were offered neoadju-
vant chemotherapy prior to radical hysterectomy plus adjuvant
radiotherapy as indicated, while those from all other referral units
were offered radical hysterectomy alone (n¼5), radical hyster-
ectomy followed by adjuvant radiotherapy (n¼3), chemora-
diotherapy (n¼13; Green et al, 2001) or lymph node dissection
and radiotherapy (n¼2) as indicated. This reflected the clinical
practice at these centres at that time. Neoadjuvant chemotherapy
consisted of methotrexate 300mgm
 2 (with folinic acid 15mg 12h
for six doses as rescue after 24h), bleomycin 30mgm
 2 and
cisplatin 60mgm
 2 repeated twice weekly for three courses.
Radical hysterectomy was performed within 7 days of completion
of neoadjuvant chemotherapy. Adjuvant radiotherapy consisted of
45Gy in 25 fractions to a volume that encompassed the top of the
sacroiliac joints to the bottom of the obturator foramen in all
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lcases. Chemoradiotherapy regime in the control group consisted of
50Gy fractionated over 5 5.5 weeks with cisplatin 40mgm
 2
weekly over that time period, followed by high dose rate
intracavitary brachytherapy tailored to the individual (usually
14Gy in two insertions). Three patients in the control group
received additional radiation to the para-aortic nodes.
Magnetic resonance imaging
The endovaginal receiver coil was of solenoid geometry design,
37mm in diameter, mounted on a Delrint ring. Details of the
endovaginal coil have been described previously (deSouza et al,
1996). The coil was inserted into the vagina and positioned around
the cervix by manipulation of the handle, then immobilised by an
external clamp. All patients were able to tolerate the coil for the
length of the examination (30–40min) and in no case was the
examination terminated because of patient discomfort.
Imaging was performed either at 0.5 or 1.5T (Apollo or Eclipse,
Marconi Medical Systems, Highland Heights, OH, USA) using
transverse to the cervix T1-weighted spin echo (SE 720-820/20
(TR/TE) ms), and sagittal T2-weighted fast spin-echo (FSE 2500/80
(TR/TE) ms) sequences. Contiguous slices 2–3mm thick were
acquired with a 192 256 matrix, two to four signal averages and a
12-cm field of view. On completion of the endovaginal study, the
coil was removed. An external four-channel pelvic phased array
coil (Picker International, Highland Heights, OH, USA) was then
used to acquire sagittal and transverse to the cervix T2-weighted
FSE images with 6mm contiguous slices, a 192 256 matrix, two
to four signal averages and a 25–35cm field of view at 0.5T.
Additional coronal STIR sequences were also done for assessment
of pelvic lymphadenopathy.
In vivo
1H-MRS
T2-weighted images sagittal and transverse to the cervix were used
to position a 3.4cm
3 voxel centrally within the cervical mass.
Shimming on the voxel was done using a point-resolved spectro-
scopy sequence (PRESS) technique to give the minimum water line
width at half height. This value was recorded. Localisation and
acquisition of
1H-MR spectra were performed using the PRESS
technique (TR, 1600ms, TEs, 68, 135 and 270ms). The total
acquisition time for each echo time was 3.8min. Water suppres-
sion was obtained with three initial chemical shift selective
saturation (CHESS) pulses. Resonance peaks were all phased to
choline-containing compounds and their chemical shifts assigned
relative to that of the total choline peak at 3.2p.p.m.
Data analysis
MR imaging studies The presence of a mass within the cervix was
recorded and tumour volumes measured on the T2-weighted
sagittal images by drawing a region of interest around the inter-
mediate signal-intensity mass of tumour on each slice and multi-
plying the total area by slice thickness. This was done three times
in each patient by a single observer (NdS) and a o1% variation in
volume obtained between the readings. Previous correlation of
such measurements with volumes measured on pathology speci-
mens has shown excellent agreement (Wagenaar et al, 2000).
In vivo MRS studies The voxel of spectroscopic data acquisition
was displayed on consecutive T2-weighted sagittal slices. The
presence of triglyceride-CH2 (1.3p.p.m.) and -CH3 (0.9p.p.m.)
resonances, choline-containing compounds (Cho) (3.2p.p.m.),
creatine plus phosphocreatine (Cr) (3.0p.p.m.) and 2 p.p.m. peaks
was noted. In some cases, the triglyceride signals were observed to
be markedly out of phase compared with the choline resonance.
As there was no evidence that this was due to a first-order phase
shift, it was assumed that this represented contamination from
triglyceride signals outside the voxel due to imperfect slice select
pulses, compounded by patient motion. When the water line width
at half height was o15Hz and spectral quality was adequate, peak
area of choline at TE 135ms was computed using the scanner
software. Owing to the difficulty in determining absolute concen-
trations, tissue water was used as an internal standard. As the
concentration of water in normal and cancer tissue is uniform to a
first-order approximation (Mahon et al, 2004), contamination
from out-of-voxel water was not considered. Peak areas of choline,
CH2 and 2p.p.m. peak were analysed relative to the estimated peak
area of the T2 corrected unsuppressed water signal from the voxel
and expressed as arbitrary units (a.u.).
Statistics
Statistical analysis was performed using SPSS, version 10.1 for
Windows. For tumour volumes, as the data were not normally
distributed, volumes in the neoadjuvant chemotherapy vs those
in the conventionally treated control group were compared with
the Mann–Whitney U test. The reduction in tumour volume
before and after neoadjuvant chemotherapy was compared using a
paired t-test. For in vivo MRS data, the levels of resonances in
phase with choline of triglyceride-CH2 Cho, and signal at 2p.p.m.
before and after a 6-week course of neoadjuvant chemotherapy
were compared using a paired t-test. Survival was calculated by the
product limit method of Kaplan and Meier (Statistica version 5.0,
Statsoft, Tulsa, USA).
RESULTS
In all, 22 patients aged 28–60 years (mean, s.d. 43.3710y) were
included in the neoadjuvant chemotherapy arm (18 stage Ib
410cm
3, 4 stage IIb) and 23 patients aged 33–69 years (mean, s.d.
44.778.5y) were included in the control arm (16 stage Ib
410cm
3, 1 stage IIa, 6 stage IIb). There was no significant
difference in age between the women treated with neoadjuvant
chemotherapy prior to Wertheim’s hysterectomy and those in the
control group (treated with radical surgery or chemoradiotherapy)
(P¼0.63).
MR imaging
In the neoadjuvant chemotherapy group, tumour volumes ranged
from 11.5 to 70cm
3 pre-chemotherapy (median and quartiles 35.8,
17.8, 57.7cm
3, Table 1). Post chemotherapy scans were done in 19
cases (three failed to attend) and tumour volumes ranged from 0.9
to 87.0cm
3 (median, quartiles 7.5, 3.0, 19.0cm
3). There was a
highly significant reduction in tumour volume (median reduction
68.6cm
3) after treatment (P¼0.002, Figure 1). A 450% reduction
in tumour volume (partial response) was seen in 14 out of 19 cases
(73.7%). Tumour volume decreased after chemotherapy in 16
(84%) out of 19 cases (Figure 2); in two cases it remained the same
Table 1 MR findings in the neoadjuvant chemotherapy vs control groups
MRI features
Neoadjuvant
chemotherapy
group Control group
MRI tumour volume pre
(median, quartiles)
35.8 (17.8, 57.7) cm
3 23.0 (15.0, 37.0) cm
3
MRI tumour volume post
(median, quartiles)
7.5 (3.0, 19.0) cm
3
Parametrial extension % 59.1 (13/22) 56.5 (13/23)
Enlarged nodes % 77.3 (17/22) 60.9 (14/23)
Neoadjuvant chemotherapy in cervical cancer
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land in one case there was a doubling of tumour volume after 6
weeks of chemotherapy. Tumour volume in the control group
ranged from 10.1 to 72cm
3 (median and quartiles 23.0, 15.0,
37.0cm
3). Tumour volumes were not significantly smaller than
those in the neoadjuvant chemotherapy arm (Mann–Whitney
U-test, P¼0.068). Although the neoadjuvant chemotherapy group
had more patients with tumour volumes greater than 40cm
3, our
data show that volume has less impact on mortality when it
exceeds 20cm
3 (Soutter et al, in press). Distribution of tumour
volume in the groups is shown in Figure 3. The characteristics of
the two groups in terms of MR features (parametrial extension,
enlarged lymph nodes) are shown in Table 1. The histological
findings after radical hysterectomy in the two groups (parametrial
extension, lymph node positivity) for the two groups are shown in
Table 2.
MR spectroscopy
Nine of 22 patients had in vivo MR spectroscopy before and after
neoadjuvant chemotherapy. A typical in vivo spectrum from these
patients is illustrated and showed peaks from choline (3.2p.p.m.),
a peak at 2p.p.m. and CH2 at 1.3p.p.m. (Figure 4). The concen-
tration of water in the tumour pre (mean, s.d. 1.970.8 10
6 a.u.)
and post (mean, s.d. 2.671.7 10
6 a.u.) chemotherapy was similar
to a first-order approximation (P¼0.14). Levels of choline pre
and post neoadjuvant chemotherapy were 4.6978.13 10
 4 and
2.1971.42 10
 4 a.u. (mean, s.d.), respectively, but differences
were not statistically significant (P¼0.39). Levels of the 2p.p.m.
peak pre and post neoadjuvant chemotherapy were 4.78713.15 
10
 4 and 1.2471.27 10
 4 a.u. (mean, s.d.), respectively, but
differences were not statistically significant (P¼0.46). Levels of the
CH2 peak pre and post neoadjuvant chemotherapy were 3.857
5.53 10
 4 and 1.2372.4 10
 4 a.u. (mean, s.d.), respectively,
which just approached significance (P¼0.05).
Outcome
The median length of follow-up of 23 surviving patients was 1043
days (range 510–2258 days) and 22 women relapsed and died.
There was no difference in 3-year survival between the women
receiving neoadjuvant chemotherapy and those in the control
group treated primarily with radical surgery or chemoradiotherapy
(49.1 vs 46.0%, P¼0.94, Figure 5). In the neoadjuvant chemother-
apy group, eight of 11 (72.7%) patients with positive lymph nodes
died of disease, while only three of 11 (27.3%) patients with
negative lymph nodes died of disease.
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Figure 1 Tumour volumes pre and post neoadjuvant chemotherapy,
showing response in individual cases.
Figure 2 Sagittal T2-weighted fast spin-echo (FSE 3000/88ms (TR/
effective TE)) images before (A) and after (B) three cycles of neoadjuvant
chemotherapy. The intermediate signal intensity tumour confined to the
cervix (arrows) reduced from 50 to 18cm
3 in volume.
Figure 3 Tumour volume distribution prior to treatment in the
neoadjuvant chemotherapy group and the control group.
Table 2 Histological features in the neoadjuvant chemotherapy vs
control groups
Histological
features
Neoadjuvant
chemotherapy
group (%) Control group (%)
Type
Squamous 72.7 (16/22) 73.9 (17/23)
Adenocarcinoma 13.6 (3/22) 13.0 (3/23)
Adeno-squamous 9.1 (2/22) 4.3 (1/23)
Other 4.5 (1/22) 4.3 (1/23)
Grade
1 4.5 (1/22) 4.3 (1/23)
2 45.5 (10/22) 34.8 (8/23)
3 50.0 (11/22) 60.9 (14/23)
Lymphovascular space
invasion
47.6 (10/21)
1 patient had RT to
primary site
42.9 (6/14; 9 biopsies
inadequate to assess)
Parametrial invasion 33.3 (7/21) 12.5 (1/8; 8 had RHND)
Lymph node
involvement
50.0 (11/22) 40.0 (4/10; 10 had LND)
Neoadjuvant chemotherapy in cervical cancer
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lDISCUSSION
Our study shows a reduction in tumour volume in 84% of patients
following neoadjuvant chemotherapy, two patients showed no
response and one patient’s disease progressed. The reduction in
tumour volume, following neoadjuvant chemotherapy, offers the
potential of facilitating primary surgery. In addition, it may serve
to control micrometastatic disease and so improve survival.
Previous studies have relied on clinical evaluation by pelvic
examination with or without ultrasonography to assess the
response (Eddy et al, 1995; Lai et al, 1997; Sardi et al, 1997;
Benedetti-Panici et al, 1998; Hwang et al, 2001). Reductions in
tumour volume of up to 100% with as many as 15–20% having
complete clinical response after three cycles of chemotherapy (Lai
et al, 1997; Benedetti-Panici et al, 1998) have been reported, but on
comparison with subsequent histopathology these assessments
have been shown to be inaccurate (Eddy et al, 1995). MR imaging
using an endovaginal receiver coil allows an improved signal-to
noise ratio immediately adjacent to the region of interest and
provides accurate assessment of tumour volume and parametrial
extension (deSouza et al, 2000). The median tumour volume was
reduced by 79% in our study. However, our tumour volume
measurements were made by drawing a region of interest around
an intermediate to high signal intensity mass within the cervix, so
it was not possible to distinguish treated from viable tumour. It
may well be that our post-treatment measurements included non-
viable tumour.
Tumour necrosis and regression are often associated with dense
fibrosis, which may complicate surgical management. In our
cohort, operability after neoadjuvant chemotherapy was not
compromised. All patients receiving neoadjuvant chemotherapy
were judged on MR imaging to be operable at the outset. No
patient was subsequently found to be inoperable, either because of
disease progression or because of tissue fibrosis/inflammation
following chemotherapy. Paladini et al (1995) have reported an
intra-operative complication rate of 13.3% for these tumours, with
an overall post-operative complication rate of 4.4%, which was not
significantly different from the reported complication rate for
radical surgery without neoadjuvant chemotherapy.
The molecular profile of tumours in vivo may be probed using
1H-MR spectroscopy to non-invasively identify metabolites and
other cell components that have sufficient mobility to be MR
detectable (Le Moyec et al, 1992; Kuesel et al, 1994a). Previous
reports have shown that the MR spectra of biopsy samples from
invasive cancer of the cervix are characterised by resonances of
mobile triglycerides (Delikatny et al, 1993). Use of an endovaginal
receiver coil makes it possible to obtain in vivo spectra from the
tumour, which would not otherwise be available. We have detected
the presence of positive triglyceride-CH2 resonances in 74% of
cervical tumours in vivo using this technique (Mahon et al, 2004).
Positive triglyceride signals were not detected in normal control
women. This finding was corroborated on ex vivo MR spectro-
scopy studies of uterine cervical tissue from the same women.
The origin of these triglycerides is debated. High lipid levels in
glioblastoma biopsy samples have been correlated with necrosis
(Kuesel et al, 1994b), but are also seen in tumours with no
apparent necrosis (Negendank and Sauter, 1996). Levels of MR
visible lipids also have been shown to be directly proportional to
the number of apoptotic cells (Blankenberg et al, 1997). In both
uni- and multivariate analysis, the apoptotic index has been shown
to be a strong predictor of recurrence-free survival (Costa et al,
2001). It therefore may be possible to monitor non-invasively in
vivo using MR spectroscopy parameters that predict favourable
prognosis.
We did not see any significant differences in choline-containing
compounds before and after chemotherapy. Choline-containing
compounds differentially accumulate in normal and malignant
tissue, and have been localised, as shown in in vivo 1H MR
spectroscopy of brain tumours (Vigneron et al, 2001) prostate
cancer (Kurhanewicz et al, 1996) and breast cancer (Kvistad et al,
1999). Although these studies have shown that the malignant
regions have elevated total choline resonances at 3.2p.p.m.
compared to normal tissue, our in vivo results show no significant
differences between the levels of total choline detected in cancer
compared with normal (Mahon et al, 2004), and no statistically
significant reduction in choline-containing compounds were seen
after neoadjuvant chemotherapy. Partial volume effects related to
tissue heterogeneity within the voxel are likely to be responsible.
Figure 4 Proton magnetic resonance spectra (
1H PRESS, TR¼1600ms;
TE¼135ms) acquired from a 3.75cm
3 voxel within the tumour before
(A) and after (B) three cycles of neoadjuvant chemotherapy. Triglyceride
signal (1.3p.p.m.) in-phase with choline-containing compounds (3.2p.p.m.)
is reduced in (B).
Figure 5 Cumulative proportions surviving in each group. The solid line
shows the Kaplan–Meier survival curve for the neoadjuvant chemotherapy
group and the dashed line is the survival curve for the control group. The
vertical dashes are censored observations and the open symbols are
deaths.
Neoadjuvant chemotherapy in cervical cancer
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lSurvival in both the neoadjuvant chemotherapy group and the
control group was equally poor. Lymph node involvement in both
groups was twice that was quoted for similar stage tumours in the
literature. In other reports, for tumours clinically assessed as
44cm diameter, a 11–25% lymph node involvement resulted in
overall 5-year survival figures between 82 and 74% (Eddy et al,
1995; Sardi et al, 1997; Benedetti-Panici et al, 1998; Hwang et al,
2001). Similarly, a randomised study by Chang et al. (2000),
comparing neoadjuvant chemotherapy followed by radical hyster-
ectomy with radical radiotherapy in bulky stage I disease, showed
a 2-year cumulative survival of 81% for the neoadjuvant
chemotherapy arm, but no significant difference between that
and the control arm in disease-free or overall survival. The lower
survival figures in both our groups reflect the selection of a poorer
prognostic group at the outset in terms of tumour burden and
lymph node metastases. A more recent phase II study of 441 stages
Ib2-III cervical cancers randomised to neoadjuvant chemotherapy
plus radical surgery vs radical radiotherapy showed an overall 5-
year survival of 64.7% for the Stage Ib2–IIb subgroup in the
neoadjuvant chemotherapy arm (Benedetti-Panici et al, 2002). This
is more in keeping with our data.
Neoadjuvant chemotherapy has also been advocated for patients
younger than 50 years (mean 38 years), where an overall 5-year
survival of 84% was seen in bulky Ib and IIa tumours (Aoki et al,
2001). The incidence of parametrial invasion and lymph node
invasion in these patients was 29%, and 29% invaded less than
two-thirds into the cervical stromal on MR imaging. In our cohort,
two of seven patients over 50 years of age died of disease by 2
years, while eight of 15 patients under the age of 50 died of disease
by 2 years, indicating that, in our patients with large tumour
volumes, parametrial extension and lymphadenopathy on imaging,
age was probably not a significant factor in determining survival.
The high response rates to cisplatin-based regimes in phase II
studies (Eifel, 2000) have led to randomised trials comparing
neoadjuvant chemotherapy plus primary treatment with primary
treatment alone. Regimes described vary from single agent
cisplatin 40mgm
 2 to double or triple agent therapy combining
cisplatin 43–80mgm
 2 with bleomycin 15–30mgm
 2 and with
the addition of vinblastine 4mgm
 2 or vincristine 1mgm
 2.
Numbers of cycles varied between two and six, with reports of
continued response up to five cycles (Hwang et al, 2001). We
used a regimen from Benedetti-Panici et al (1991), modified from
three times weekly to twice weekly, with a reduced dose of
cisplatin. This regimen causes nausea, vomiting and fatigue, but
no major haematological toxicity, provided the folinic acid is taken
on time.
Our study shows that, although there is a significant reduction
in tumour volume and –CH2 triglyceride levels after neoadjuvant
chemotherapy, there is no survival advantage. However, in our
small non-randomised cohort, the prognostic factors were not
entirely balanced: although not significant, the neoadjuvant group
had larger tumours, a higher prevalence of lymphovascular
invasion, parametrial invasion and enlarged nodes, which, taken
together, suggest that they may have been a slightly worse
prognostic group. An EORTC trial (55994) is comparing neoadju-
vant chemotherapy followed by radical surgery with chemoradia-
tion, in order to determine survival benefit.
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